Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Closes $73M Buy of Panomics

NEW YORK (GenomeWeb News) – Affymetrix said today that it has closed its purchase of the genetic and cellular analysis company Panomics for $73 million in cash.
 
The company said today that the addition of Panomics will enable “a more complete customer workflow, beginning with whole-genome Affymetrix microarray studies and then focusing on genes and proteins of interest with the Panomics products.” 
 
Affy, which announced its plan to buy the company in November, said that it will discuss the impact of the acquisition during its fourth-quarter conference call on Jan. 29, 2009.
 
Panomics, a privately held company based in Fremont, Calif., offers reagents and products for use in research initiatives including intracellular pathway analysis, cell signaling, and gene expression profiling. Panomics’ assays do not require nucleic acid extraction or amplification, which streamlines gene expression, copy number, and cytogenetics applications, Affy said.
 
At the time the deal was announced, Affy President Kevin King said that it would allow his company “to enter new high-growth market segments, enhance our recently acquired liquid array platform, and create further operating leverage.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.